Welcome to CUBICIN.com

 

The information on this site is intended for health care professionals in the United States, its territories, and Puerto Rico and is not intended for the general public.

Announcements

Discontinuation: The sale of CUBICIN® (daptomycin for injection) 500 mg/10 mL single-dose vial, NDC 67919-011-01, has been discontinued. CUBICIN® RF (daptomycin for injection) 500 mg/10 mL single-dose vial, NDC 67919-012-01 remains available.

Voluntary Recall: One lot of CUBICIN® (daptomycin for injection) 500 mg for intravenous use, Lot 934778, Exp. June 2022, is being recalled by Merck effective October 19, 2021. For more information, please contact the Merck National Service Center at (800) 672-6372, select prompt #1, then please hold for a representative, Monday to Friday 8:00 AM to 7:00 PM (EST).



This site is intended for health care professionals in the United States, its territories, and Puerto Rico.

Terms of Use | Privacy Policy | Cookie Preferences

More

Selected Important Safety Information
Anaphylaxis/hypersensitivity reactions, which may be life-threatening, have been reported with CUBICIN use. If an allergic reaction occurs, discontinue CUBICIN or CUBICIN RF and treat appropriately.